Our pipeline is focused on retinal disease
PIPELINE
We are tackling the leading causes of blindness, beginning with wet age-related macular degeneration (AMD) and diabetic retinopathy (DR)
| AXPAXLI™ | PRECLINICAL | PHASE 1 | PHASE 2 | PHASE 3 | FDA APPROVAL |
|---|---|---|---|---|---|
| (also known as OTX-TKI), an investigational axitinib hydrogel administered by intravitreal injection | Early Clinical Stage | Mid Clinical Stage | Registrational Phase |
Wet AMD* PHASE 3: Registrational Phase
| Wet AMD* PHASE 3: Registrational Phase | |
CLINICAL TRIAL SUMMARY:
AXPAXLI is being investigated for the treatment of wet AMD. AXPAXLI targets with axitinib – a highly potent tyrosine kinase inhibitor (TKI) with strong selectivity for pan-VEGF receptor inhibition – and is delivered with ELUTYX™, our proprietary fully bioresorbable hydrogel technology1-4
NPDR† PHASE 3: Registrational Phase
| NPDR† PHASE 3: Registrational Phase | |
CLINICAL TRIAL SUMMARY:
AXPAXLI is being investigated for the treatment of non-proliferative diabetic retinopathy (NPDR) without center-involved diabetic macular edema (DME). AXPAXLI targets with axitinib – a highly potent tyrosine kinase inhibitor (TKI) with strong selectivity for pan-VEGF receptor inhibition – and is delivered with ELUTYX, our proprietary fully bioresorbable hydrogel technology1-4
| OTX-TIC | PRECLINICAL | PHASE 1 | PHASE 2 | PHASE 3 | FDA APPROVAL |
|---|---|---|---|---|---|
| an investigational travoprost hydrogel administered by intracameral injection | Early Clinical Stage | Mid Clinical Stage | Registrational Phase |
Glaucoma
and ocular
hypertension 
| Glaucoma and ocular hypertension | |
CLINICAL TRIAL SUMMARY:
OTX-TIC is being investigated for the treatment of glaucoma and ocular hypertension. OTX-TIC targets with travopost, a prostaglandin analog, and is delivered with ELUTYX, our proprietary fully bioresorbable hydrogel technology4
Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this website.
All investigational product candidates are currently undergoing clinical evaluation. This content is not intended to convey any conclusion of safety or efficacy, and there is no guarantee that any product candidate will successfully complete development or gain FDA approval or other regulatory authority approval.
References
* Age-related Macular Degeneration (AMD)
† Non-proliferative Diabetic Retinopathy (NPDR)
1. Zhao Y, et al. Oncologist. 2015;20(6):660-673. 2. Gross-Goupil M, et al. Clin Med Insights Oncol. 2013;7:269-277. 3. Liang C, et al. Mol Ther Oncolytics. 2022;24:577-584. 4. Blizzard CD, et al. Inventors, Ocular Therapeutix, Inc., Assignee. Ocular implant containing a tyrosine kinase inhibitor. US Patent 11,439,592 B2. September 13, 2022.